Business Context and Reporting Period
This Form 8-K Current Report was filed by 180 Life Sciences Corp. (not Forum Markets Inc.) on June 9, 2021. The registrant is a Delaware corporation with principal executive offices in Menlo Park, CA. The report primarily addresses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of new directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on non-financial corporate events. The only financial data disclosed relates to director compensation:
- Director Retainer: $40,000 per compensation year.
- Committee Fees: $5,000 for Compensation or Nominating/Governance Committees; $7,500 for Audit or Risk Committees.
- Chairperson Fees: $10,000 for Compensation or Nominating/Governance Chairs; $15,000 for Audit or Risk Chairs.
- Equity Grant: Options to purchase shares with a value of $425,000 (based on Black-Scholes calculation) for each new appointee.
Material Changes
The Board of Directors increased the number of board members from seven to nine. Two new directors were appointed:
- Frank Knuettel II, MBA: Appointed as a Class I director.
- Pamela G. Marrone, PhD: Appointed as a Class II director.
Additionally, the effective dates for two previously announced directors (Russell T. Ray and Teresa DeLuca) were extended to align with the new appointments. Both new appointees were determined to be "independent" under NASDAQ Capital Market rules.
Outlook, Risks, and Unusual Items
Management Commentary: The Board cited Mr. Knuettel's experience in finance, venture capital, and the cannabis/biosciences sectors, and Dr. Marrone's extensive background in bio-ag, agtech, and commercialization as qualifications for their service.
Unregistered Sales of Equity: The company plans to claim an exemption from registration under Section 4(a)(2) and/or Rule 506 of Regulation D for the initial option grants, as the recipients are accredited investors and the securities are for investment only.
Compensation Arrangements: New directors entered into offer letters and standard indemnity agreements. The option grants vest monthly (1/48th of the balance) over four years, with a minimum share count adjustment mechanism if the initial grant falls below 100,000 shares.
Investor Verification Checklist
- Verify the exact effective date of the new director appointments (earlier of the business day following the 2020 10-K filing or June 28, 2021).
- Confirm the specific number of shares included in the $425,000 option grants based on the closing sales price on the grant date.
- Review the full text of the Offer Letters (Exhibit 10.1) and Stock Option Agreements (Exhibit 10.2) for complete terms.
- Check the company's 10-K filing to confirm the total number of authorized shares and potential dilution from these new grants.